Eunju Choi

Ms. Eunju Choi

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 May 2025 in Kidney Research and Clinical Practice
Verified
Journal Article
Open access
PDF file
SKSungmin Kim
Sungmin Kim
HJHao Jin
Hao Jin
ECEunju Choi
Eunju Choi
ELEun-Ok Lee
Eun-Ok Lee
YLYU RAN LEE
YU RAN LEE
Byeong Hwa JeonByeong Hwa Jeon
Byeong Hwa Jeon
Background: The role of apurinic/apyrimidinic endonuclease 1/redox factor-1 (APE1/Ref-1) in renal fibrosis development remains unclear. This study aimed to investigate the role of APE1/Ref-1 deficiency on renal fibrosis and elucidate the underlying mechanisms using a unilateral ureteral obstruction (UUO) mouse model and HK-2 cells in vitro. Methods: Male wild-type and heterozygous APE1/Ref-1 +/-mice underwent UUO or sham surgery. Renal tissue was collected at 7 and 14 days after UUO. APE1/Ref-1 expression, histological changes, fibrosis markers (collagen I, α-smooth muscle actin [α-SMA], vimentin, transforming growth factor-β1 [TGF-β1]), macrophage infiltration (F4/80, CD68), 8-hydroxy-2'-deoxyguanosine (8-OHdG), and apoptosis (terminal deoxynucleotidyl transferase dUTP nick end labeling [TUNEL]) were assessed. In human kidney-2 (HK-2) cells, APE1/Ref-1 was knocked down using small interfering RNA, and epithelial-mesenchymal transition (EMT) markers (vimentin, α-SMA) were evaluated following TGF-β1 stimulation. Results: UUO upregulated APE1/Ref-1 expression in wild-type mice, but this was attenuated in heterozygous APE1/Ref-1 +/-mice. While both genotypes displayed tubular injury, no significant differences in tubular injury scores or renal function markers were observed. Heterozygous APE1/Ref-1 +/-mice exhibited exacerbated renal fibrosis compared to wild-type mice, as shown by increased collagen I, α-SMA, TGF-β1, and vimentin levels. Macrophage infiltration (CD68, F4/80) was significantly elevated in heterozygous APE1/Ref-1 +/-mice after UUO. Increased 8-OHdG and TUNEL-positive cells indicated enhanced oxidative damage and apoptosis in heterozygous APE1/Ref-1 +/-mice. In HK-2 cells, APE1/Ref-1 knockdown induced the upregulation of vimentin and α-SMA, suggesting a role in EMT regulation. Conclusion: APE1/Ref-1 deficiency exacerbates fibrosis, macrophage infiltration, and apoptosis. APE1/Ref-1 also modulates EMT in vitro, highlighting its protective function in chronic kidney disease.

12 November 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
HJHAO JIN
HAO JIN
YLYU RAN LEE
YU RAN LEE
SKSungmin Kim
Sungmin Kim
ECEunju Choi
Eunju Choi
KLKa-Young Lee
Ka-Young Lee
Byeong Hwa JeonByeong Hwa Jeon
Byeong Hwa Jeon
Background: Triple-negative breast cancer (TNBC) is a highly aggressive subtype with limited therapeutic options due to the lack of estrogen, progesterone, and HER2 receptors. This study investigated the synergistic anticancer effects of recombinant human apurinic/apyrimidinic endonuclease 1/redox factor-1 (rhAPE1/Ref-1) and acetylsalicylic acid (ASA), a combination that has not been previously tested in vivo. Methods: We treated MDA-MB-231 TNBC cells with rhAPE1/Ref-1, ASA, or their combination to assess cell viability and apoptosis in vitro. In vivo, a murine xenograft model was established to evaluate the efficacy of the combination treatment on tumor growth, tumor-specific biomarkers, and key apoptotic proteins. The safety profile of the combination therapy was also assessed by monitoring hematological parameters. Results: While monotherapy with either rhAPE1/Ref-1 or ASA had minimal effects, their combination significantly reduced cell viability and enhanced apoptosis in vitro by increasing DNA fragmentation. These synergistic cytotoxic effects were significantly inhibited by the receptor for advanced glycation end-products (RAGE) siRNA, suggesting that RAGE acts as an important mediator. In the xenograft model, the combination treatment suppressed tumor growth by approximately 70%, an effect comparable to paclitaxel (PTX). This was confirmed by a significant reduction in the plasma levels of TNBC biomarkers (CEA, CA27-29, and CA15-3) and increased tumor apoptosis via the upregulation of p53 and Bax and downregulation of Bcl-2. Notably, ASA, alone or combined with rhAPE1/Ref-1, induced the expression of RAGE in MDA-MB-231 tumors. In contrast to PTX, the combination of rhAPE1/Ref-1 and ASA did not cause hematological toxicity, such as anemia or thrombocytopenia. Conclusions: The combination of rhAPE1/Ref-1 and ASA represents a promising new therapeutic strategy for TNBC by enhancing apoptosis and significantly inhibiting tumor progression in a mouse xenograft model.